Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
BTG Commences Phase IIa Study of Multiple Sclerosis
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Alerting Network Dysfunction in Early Multiple Sclerosis.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Glatiramer acetate does not protect from acute ischemic stroke in mice.
RILUTEK®
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
A systematic review of research undertaken in vocational rehabilitation for people with multiple sclerosis.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
[Nicolau syndrome after administration of glatiramer acetate].
Calcitriol Modulates the CD46 Pathway in T Cells.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Pages